HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...
SAN DIEGO — Allogeneic stem cell transplant is associated with a significant survival benefit in patients with NPM1-mutated acute myeloid leukemia (AML) who are in their first complete remission and ...
SELLAS Life Sciences Group, Inc. has announced promising preclinical results for SLS009, a selective CDK9 inhibitor, in treating TP53 mutated Acute Myeloid Leukemia (AML) cells, which typically have ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
1.5-year clinical outcomes in patients with triple-mutated AML who were positive and negative for MRD before allo-HSCT. This paper explores the clinical outcomes of allogeneic hematopoietic stem cell ...
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and ...
Late Nonrelapse Mortality: A Hidden Risk in Triplet Therapy for IDH-Mutated AML? The following represents disclosure information provided by the author of this manuscript. All relationships are ...
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National ...
The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Ziftomenib's efficacy was evaluated among 112 adults in an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results